Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05780905 · ClinicalTrials.gov registry record · Phase 4

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

A Phase 4 study of Diabetes Mellitus, Type 2 and Stroke (CVA) or Transient Ischemic Attack, sponsored by University of Washington.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT05780905 is a Phase 4 study of Diabetes Mellitus, Type 2 and Stroke (CVA) or Transient Ischemic Attack that is actively recruiting participants, run by University of Washington. The registered enrollment target is 50 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05780905, a Phase 4 study of Diabetes Mellitus, Type 2 and Stroke (CVA) or Transient Ischemic Attack, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.

Conditions Studied

Diabetes Mellitus, Type 2 Stroke (CVA) or Transient Ischemic Attack

Interventions

  • OTHER Placebo
  • DRUG Semaglutide Auto-Injector

Study Locations (1)

Washington

  • University of Washington - Harborview Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-01-11
Est. Completion 2026-12-31
Phase Phase 4

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05780905

The ClinicalTrials.gov registry entry for NCT05780905 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05780905 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT05780905 about?

NCT05780905 is a clinical study titled "Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes". A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with...

What is the current status of trial NCT05780905?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2024-01-11. Estimated completion is 2026-12-31.

What conditions does trial NCT05780905 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack.

What interventions are being tested in trial NCT05780905?

The interventions under investigation include: Placebo (OTHER), Semaglutide Auto-Injector (DRUG).

Who is sponsoring clinical trial NCT05780905?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05780905 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Stroke (CVA) or Transient Ischemic Attack

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.